Evidence map›Paper›PMID 32678853›Full record

ArticlePloS one2020

An Erg11 lanosterol 14-α-demethylase-Arv1 complex is required for Candida albicans virulence.

Michelle L Villasmil, Antonio Daniel Barbosa, Jessie Lee Cunningham, Symeon Siniossoglou, Joseph T Nickels

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Insights intomSphere · 2026
    Article
  3. Article
  4. Review
  5. Role of ERG11 and MDR1 genes in cycloheximide and multidrug resistance in Candida species.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  6. Review
  7. The Effect of Honokiol on Ergosterol Biosynthesis and Vacuole Function inJournal of microbiology and biotechnology · 2020
    Article
  8. Arv1; a "Mover and Shaker" of Subcellular Lipids.Contact (Thousand Oaks (Ventura County, Calif.))
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Michelle L VillasmilInstitute of Metabolic Disorders, Genesis Biotechnology Group, Hamilton, New Jersey, United States of America.
Antonio Daniel BarbosaCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Jessie Lee CunninghamInstitute of Metabolic Disorders, Genesis Biotechnology Group, Hamilton, New Jersey, United States of America.
Symeon SiniossoglouCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Joseph T NickelsInstitute of Metabolic Disorders, Genesis Biotechnology Group, Hamilton, New Jersey, United States of America.ORCID 0000-0001-9984-3056
Genesis HealthCare · USUniversity of Cambridge · GBRutgers, The State University of New Jersey · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azole resistant fungal infections remain a health problem for the immune compromised. Current therapies are limited due to rises in new resistance mechanisms. Therefore, it is important to identify new drug targets for drug discovery and novel therapeutics. Arv1 (are1 are2 required for viability 1) function is highly conserved between multiple pathogenic fungal species. Candida albicans (C. albicans) cells lacking CaArv1 are azole hypersusceptible and lack virulence. Saccharomyces cerevisiae (S. cerevisiae) Scarv1 cells are also azole hypersusceptible, a phenotype reversed by expression of CaArv1, indicating conservation in the molecular mechanism for azole susceptibility. To define the relationship between Arv1 function and azole susceptibility, we undertook a structure/function analysis of ScArv1. We identified several conserved amino acids within the ScArv1 homology domain (ScAhd) required for maintaining normal azole susceptibility. Erg11 lanosterol 14-α-demethylase is the rate-limiting enzyme in sterol biosynthesis and is the direct target of azole antifungals, so we used our ScArv1 mutants in order to explore the relationship between ScArv1 and ScErg11. Specific ScArv1 mutants ectopically expressed from a low copy plasmid were unable to restore normal azole susceptibility to Scarv1 cells and had reduced Erg11 protein levels. Erg11 protein stability depended on its ability to form a heterodimeric complex with Arv1. Complex formation was required for maintaining normal azole susceptibility. Scarv1 cells expressing orthologous CaArv1 mutants also had reduced CaErg11 levels, were unable to form a CaArv1-CaErg11 complex, and were azole hypersusceptible. Scarv1 cells expressing CaArv1 mutants unable to interact with CaErg11 could not sustain proper levels of the azole resistant CaErg11Y132F F145L protein. Caarv1/Caarv1 cells expressing CaArv1 mutants unable to interact with CaErg11 were found to lack virulence using a disseminated candidiasis mouse model. Expressing CaErg11Y132F F145L did not reverse the lack of virulence. We hypothesize that the role of Arv1 in Erg11-dependent azole resistance is to stabilize Erg11 protein level. Arv1 inhibition may represent an avenue for treating azole resistance.

Indexed as

VirulenceAmino Acid SequenceAnimalsAntifungal AgentsCandida albicansCandidiasisCytochrome P-450 Enzyme SystemDrug Resistance, FungalFungal ProteinsMaleMembrane ProteinsMiceMice, Inbred BALB CSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSequence HomologyAntifungal AgentsARV1 protein, S cerevisiaeCytochrome P-450 Enzyme SystemErg11 protein, S cerevisiaeFungal ProteinsMembrane ProteinsSaccharomyces cerevisiae ProteinsSterol 14-Demethylase

Identifiers

PMID32678853
PMCPMC7367482
OpenAlexW3043208009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.